» Articles » PMID: 19874397

Characterization and Comparison of the Properties of Sarcoma Cell Lines in Vitro and in Vivo

Overview
Journal Hum Cell
Publisher Springer
Specialty Cell Biology
Date 2009 Oct 31
PMID 19874397
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

To expand the available tools for investigating human sarcomas, we characterized the primary properties of 22 common, uncommon, and newly characterized sarcoma cell lines representing eight different histological subtypes. Throughout the characterization process we noticed that in vitro markers and assays are poor indicators of tumorigenicity and that generated xenografts often bear little resemblance to the original histopathology. In vitro properties examined included morphology, proliferation rate, cell cycle characteristics, invasiveness, and immunohistochemical expression of p53 and phospho-AKT. In vivo properties examined included days to tumor formation in NOD/SCID mice, xenograft morphology in several locations and immunohistochemical expression of Ki67, p53 and phospho-AKT. We believe that such an in depth comparison of a large cohort of sarcoma cell lines will be useful in both designing and interpreting experiments aimed at elucidating both the molecular biology and efficacy of therapeutic agents in sarcomas. However, that data generated also suggests a small set of sarcoma cell lines may be inappropriate for generalizations regarding biological behavior of specific sarcoma subtypes. Integration of functional genomics or other more sophisticated assays of cell lines may help bridge the differences in vitro and in vivo.

Citing Articles

Establishment and characterization of 18 Sarcoma Cell Lines: Unraveling the Molecular Mechanisms of Doxorubicin Resistance in Sarcoma Cell Lines.

Cho Y, Kim S, Kim H, Han I, Ku J J Transl Med. 2024; 22(1):889.

PMID: 39358756 PMC: 11445991. DOI: 10.1186/s12967-024-05700-y.


2‑D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells.

Joung H, Liu H Oncol Rep. 2024; 52(1).

PMID: 38874019 PMC: 11200159. DOI: 10.3892/or.2024.8756.


Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse.

Rijensky N, Blondheim Shraga N, Barnea E, Peled N, Rosenbaum E, Popovtzer A Mol Cell Proteomics. 2020; 19(8):1360-1374.

PMID: 32451349 PMC: 8015002. DOI: 10.1074/mcp.RA119.001876.


EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment.

Reader J, Harper A, Legesse T, Staats P, Goloubeva O, Rao G Cancers (Basel). 2019; 11(10).

PMID: 31635323 PMC: 6826612. DOI: 10.3390/cancers11101590.


Intragenic antagonistic roles of protein and circRNA in tumorigenesis.

Guarnerio J, Zhang Y, Cheloni G, Panella R, Katon J, Simpson M Cell Res. 2019; 29(8):628-640.

PMID: 31209250 PMC: 6796857. DOI: 10.1038/s41422-019-0192-1.


References
1.
Verweij J, Casali P, Zalcberg J, Lecesne A, Reichardt P, Blay J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440):1127-34. DOI: 10.1016/S0140-6736(04)17098-0. View

2.
Leach F, Tokino T, Meltzer P, Burrell M, Oliner J, Smith S . p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53(10 Suppl):2231-4. View

3.
Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y . Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res. 2005; 23(4):964-9. DOI: 10.1016/j.orthres.2005.01.010. View

4.
Hernando E, Charytonowicz E, Dudas M, Menendez S, Matushansky I, Mills J . The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007; 13(6):748-53. DOI: 10.1038/nm1560. View

5.
Latres E, Drobnjak M, Pollack D, Oliva M, Ramos M, Karpeh M . Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol. 1994; 145(2):345-55. PMC: 1887397. View